[Evaluation of the efficiency of the immune system after immunostimulation in patients with breast cancer].
67 patients with mammary carcinoma were submitted to an immunological control examination. This control comprised 14 tests which determined the efficacy of the immune systems, among others: activity of complement, properdin, lysozyme, and beta-lysin, the rate of immunoglobulins, and the behavior of leucergy, rosette tests, NBT, BLT, and tuberculin test. The thoroughly executed examinations did not show any significant difference between patients with active neoplasms and patients in remission stage. The analysis of the results achieved for patients in an advanced stage (TNM) only showed a significant increase (p less than 0.05) of IgG in stage III/IV. The patients were treated with CVF, levamisole (Decaris), and BCG. The observation period was twelve months. The results achieved were discussed in detail.
D000328:Adult; D001500:BCG Vaccine / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D003165:Complement System Proteins / Q000032:analysis; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007114:Immunization; D007136:Immunoglobulins / Q000032:analysis; D007978:Levamisole / Q000627:therapeutic use; D008239:Lysine / Q000032:analysis / Q000031:analogs & derivatives; D008875:Middle Aged; D009113:Muramidase / Q000032:analysis; D011414:Properdin / Q000032:analysis; D014750:Vincristine / Q000627:therapeutic use
D001500:BCG Vaccine; D007136:Immunoglobulins; D011414:Properdin; D007978:Levamisole; C065591:beta-lysine; D014750:Vincristine; D003520:Cyclophosphamide; D003165:Complement System Proteins; D009113:Muramidase; D008239:Lysine; D005472:Fluorouracil
Die Beurteilung der Leistung des immunologischen Systems bei Mammakarzinom-Kranken nach Immunstimulation.